• BVC Entrance
  • BioVentures

logo of UIResearch Park

Welcome to the University of Iowa Research Park, where collaborative opportunities in technology abound.

We offer corporations locating at the Park convenient, sustained access to the extensive, relevant research resources of The University of Iowa.

Here, growing enterprises have access to a state-of-the art business incubator, world-class research facilities and a dynamic faculty of scientists, physicians and engineers at one of the world’s leading public research universities.

News & Announcements

EDC Client Case Study: Viewpoint Molecular Targeting

EDC is proud to support a variety of high-impact Iowa businesses at all stages. One of those, Viewpoint Molecular Targeting, is a biotech startup based in Coralville that has developed cancer diagnostics and treatment products that are safer for patients. We hope that you enjoy reading about this exciting Iowa business that is making an impact on cancer diagnosis and treatment. 

Ground-Breaking Treatment for Hard-to-Treat Cancers

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for (NDA) AZSTARYS™ (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older. AZSTARYS consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.

Events

There are currently no results to display.